Anzeige
Mehr »
Login
Donnerstag, 23.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Micro Cap & Branchenriese: Heute rein? - Partnerschaft entfacht Übernahmefantasien!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PY7P | ISIN: US07373V1052 | Ticker-Symbol:
NASDAQ
22.01.25
21:59 Uhr
26,370 US-Dollar
0,000
0,00 %
1-Jahres-Chart
BEAM THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
BEAM THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur BEAM THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.01.Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts144More Than 40 Adult Sickle Cell Disease Patients Now Enrolled in BEACON Trial of BEAM-101; Beam Expects to Dose 30 Patients and Present Updated Data by Mid-2025 Initial Data from Phase 1/2 Trial of...
► Artikel lesen
13.01.Beam Therapeutics Inc. - 8-K, Current Report1
10.01.2 Stocks for Bulls This Year: Beam Therapeutics, Bloom Energy87
06.01.Beam Therapeutics: Chefjuristin verkauft Aktien im Wert von 30.627 US-Dollar2
06.01.Beam Therapeutics SVP Bethany J Cavanagh verkauft Aktien im Wert von 27.567 US-Dollar1
BEAM THERAPEUTICS Aktie jetzt für 0€ handeln
29.12.24Beam Therapeutics Inc. (BEAM): Is This Gene Therapy Stock a Good Buy Right Now?5
09.12.24Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains9
09.12.24Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up9
08.12.24Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology ...135NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing...
► Artikel lesen
08.12.24Beam Therapeutics Announces Positive Data From Phase 1/2 Trial Of BEAM-101 In Sickle Cell Disease678WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) announced new safety and efficacy data from its BEACON Phase 1/2 clinical trial of BEAM-101 in patients with sickle cell disease (SCD) with...
► Artikel lesen
07.12.24Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting80All Seven Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Initial Safety Profile Consistent with Busulfan Conditioning and Autologous...
► Artikel lesen
07.12.2420,800 Shares in Beam Therapeutics Inc. (NASDAQ:BEAM) Acquired by Polar Asset Management Partners Inc.9
06.12.24Beam Therapeutics Appoints Sravan Emany As CFO375WASHINGTON (dpa-AFX) - Biotechnology company Beam Therapeutics, Inc. (BEAM) announced Friday the appointment of Sravan Emany as chief financial officer (CFO), effective December 19, 2024. Emany...
► Artikel lesen
06.12.24Beam Therapeutics names Sravan K. Emany as new CFO5
06.12.24Beam Therapeutics picks Ironwood Pharmaceuticals finance and operations chief as CFO8
06.12.24Beam Therapeutics ernennt Sravan K. Emany zum neuen CFO3
06.12.24Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer81CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the...
► Artikel lesen
04.12.24Beam Therapeutics beruft Merck-Manager in den Vorstand14
04.12.24Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader8
04.12.24Beam Therapeutics Inc. - 8-K, Current Report-
Seite:  Weiter >>
52 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1